Guidelines for the automated evaluation of Elispot assays

Nature Protocols

Volumn 10, Issue 7, 2015, Pages 1098-1115

  Janetzki, Sylvia ^a   Price, Leah ^b   Schroeder, Helene ^c   Britten, Cedrik M ^d,g   Welters, Marij J P ^e   Hoos, Axel ^f  

^a ZellNet Consulting Inc ^*  (United States)

^b LBPrice Statistical Consulting Ltd   (Israel)

^c BIONTECH AG   (Germany)

^d Association for Cancer Immunotherapy (CIMT)   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACCURACY; ARTICLE; CELL ACTIVATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELISA READER; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MEMORY CELL; MONOCYTE; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; IMMUNOLOGY; LABORATORY AUTOMATION; MONONUCLEAR CELL; PROCEDURES; REPRODUCIBILITY; SINGLE CELL ANALYSIS;

AUTOMATION, LABORATORY; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; REPRODUCIBILITY OF RESULTS; SINGLE-CELL ANALYSIS;

EID: 84933059815     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2015.068     Document Type: Article

References (47)

1. Czerkinsky, C.C., Nilsson, L.A., Nygren, H., Ouchterlony, O. & Tarkowski, A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specifc antibody-secreting cells. J. Immunol. Methods 65, 109-121 (1983).
2. Streeck, H., Frahm, N. & Walker, B.D. The role of IFN-γ Elispot assay in HIV vaccine research. Nat. Protoc. 4, 461-469 (2009).
3. Saletti, G., Cuburu, N., Yang, J.S., Dey, A. & Czerkinsky, C. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat. Protoc. 8, 1073-1087 (2013).
4. Meier, T., Eulenbruch, H.P., Wrighton-Smith, P., Enders, G. & Regnath, T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur. J. Clin. Microbiol. Infect Dis. 24, 529-536 (2005).
5. + T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2836 (2013).
6. Kenter, G.G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
7. Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254-1261 (2012).
8. Sheikh, N.A. et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 62, 137-147 (2013).
9. Dillenbeck, T., Gelius, E., Fohlstedt, J. & Ahlborg, N. Triple cytokine FluoroSpot analysis of human antigen-specifc IFN-γ, IL-17A and IL-22 responses. Cells 3, 1116-1130 (2014).
10. Gazagne, A. et al. A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J. Immunol. Methods 283, 91-98 (2003).
11. Janetzki, S. et al. Results and harmonization guidelines from two large-scale international Elispot profciency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57, 303-315 (2008).
12. van der Burg, S.H. et al. Harmonization of immune biomarker assays for clinical studies. Sci. Transl. Med. 3, 108ps144 (2011).
13. + T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 57, 289-302 (2008).
14. Janetzki, S. & Britten, C.M. The impact of harmonization on ELISPOT assay performance. Methods Mol. Biol. 792, 25-36 (2012).
15. Karulin, A.Y. & Lehmann, P.V. How ELISPOT morphology refects on the productivity and kinetics of cells′ secretory activity. Methods Mol. Biol. 792, 125-143 (2012).
16. Czerkinsky, C. et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 110, 29-36 (1988).
17. Janetzki, S., Cox, J.H., Oden, N. & Ferrari, G. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302, 51-86 (2005).
18. Santos, R. et al. Improvement of IFN-γ ELISPOT performance following overnight resting of frozen PBMC samples confrmed through rigorous statistical analysis. Cells 4, 1-18 (2014).
19. Cox, J.H. et al. Results of an ELISPOT profciency panel conducted in 11 laboratories participating in international human immunodefciency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses 21, 68-81 (2005).
20. Janetzki, S. et al. Evaluation of Elispot assays: infuence of method and operator on variability of results. J. Immunol. Methods 291, 175-183 (2004).
21. Smith, S.G. et al. Identifcation of major factors infuencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS ONE 4, e7972 (2009).
22. Britten, C.M. et al. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 37, 1-2 (2012).
23. Moodie, Z. et al. Response defnition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489-1501 (2010).
24. Chattopadhyay, P.K., Gierahn, T.M., Roederer, M. & Love, J.C. Single-cell technologies for monitoring immune systems. Nat. Immunol. 15, 128-135 (2014).
25. Han, A., Glanville, J., Hansmann, L. & Davis, M.M. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol. 32, 684-692 (2014).
26. Lamoreaux, L., Roederer, M. & Koup, R. Intracellular cytokine optimization and standard operating procedure. Nat. Protoc. 1, 1507-1516 (2006).
27. Perfetto, S.P., Ambrozak, D., Nguyen, R., Chattopadhyay, P. & Roederer, M. Quality assurance for polychromatic fow cytometry. Nat. Protoc. 1, 1522-1530 (2006).
28. McNeil, L.K. et al. A harmonized approach to intracellular cytokine staining gating: results from an international multiconsortia profciency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A 83, 728-738 (2013).
29. Janetzki, S., Rueger, M. & Dillenbeck, T. Stepping up ELISpot: multi-level analysis in FluoroSpot assays. Cells 3, 1102-1115 (2014).
30. Lenders, K. et al. The effect of apoptotic cells on virus-specifc immune responses detected using IFN-γ ELISPOT. J. Immunol. Methods 357, 51-54 (2010).
31. Mallone, R. et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 163, 33-49 (2011).
32. Kutscher, S. et al. Overnight resting of PBMC changes functional signatures of antigen specifc T cell responses: impact for immune monitoring within clinical trials. PLoS ONE 8, e76215 (2013).
33. + T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol. Immunother. 63, 1199-1211 (2014).
34. Jahnmatz, M. et al. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J. Immunol. Methods 391, 50-59 (2013).
35. Shafer-Weaver, K. et al. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J. Transl. Med. 1, 14 (2003).
36. Janetzki, S. & Rabin, R. Enzyme-linked ImmunoSpot (ELISpot) for single cell analysis. Methods Mol. Biol. in the press (2015).
37. De Rose, R., Taylor, E.L., Law, M.G., van der Meide, P.H. & Kent, S.J. Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specifc ELISpot assays: analysis and strategies to ameliorate. J Immunol Methods 297, 177-186 (2005).
38. + T lymphocytes responsive to human immunodefciency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J. Infect. Dis. 178, 260-265 (1998).
39. Dubey, S. et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J. Acquir. Immune. Defc. Syndr. 45, 20-27 (2007).
40. Moodie, Z., Price, L., Janetzki, S. & Britten, C.M. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol. Biol. 792, 185-196 (2012).
41. Welters, M.J. et al. Harmonization of the intracellular cytokine staining assay. Cancer Immunol. Immunother. 61, 967-978 (2012).
42. Begley, C.G. & Ellis, L.M. Drug development: raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
43. Currier, J.R. et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol Methods 260, 157-172 (2002).
44. Maecker, H.T. et al. Use of overlapping peptide mixtures as antigens for cytokine fow cytometry. J. Immunol. Methods 255, 27-40 (2001).
45. Janetzki, S. et al. Performance of serum-supplemented and serum-free media in IFN-γ Elispot assays for human T cells. Cancer Immunol. Immunother. 59, 609-618 (2010).
46. Mascotti, K., McCullough, J. & Burger, S.R. HPC viability measurement: trypan blue versus acridine orange and propidium iodide. Transfusion 40, 693-696 (2000).
47. Weiss, A.J. Overview of membranes and membrane plates used in research and diagnostic ELISPOT assays. Methods Mol. Biol. 792, 243-256 (2012).